{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:51:32Z","timestamp":1783122692701,"version":"3.54.6"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Wilson\u2019s disease is a hereditary disorder of copper metabolism resulting mainly in hepatic, neurological, and psychiatric symptoms. Multiple sclerosis (MS) is an immune-mediated demyelinating disease affecting the central nervous system (CNS). The co-occurrence of these two, although not unheard of in literature, is still considered to be very rare and can give rise to diagnostic difficulties. Also, comorbidity in MS highly influences quality of life and disease progression, which makes the timely diagnosis and treatment of these conditions essential.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>The aim of this study is to present a patient exhibiting symptoms of both MS and Wilson\u2019s disease, as well as to conduct a detailed review of previously reported cases. The patient\u2019s neurological symptoms (sensory disorder) as well as MRI and CSF findings were characteristic for MS. The diagnosis of MS preceded that of Wilson\u2019s disease and was relatively mild in course. Currently, the patient receives cladribine as an immunomodulatory treatment after escalation from glatiramer acetate therapy. Apart from one episode of acute hepatic decompensation, during which transfusion, albumin supplementation and diuretic treatment was necessary, Wilson\u2019s disease manifested as chronic impairment of liver function. The diagnosis of Wilson\u2019s disease was established by the analysis of serum coeruloplasmin levels, histological examination and genetic findings. Continuous oral penicillamine therapy led to the slow normalization of hepatic function and significant amelioration of the patient\u2019s symptoms. Correlating with cases previously reported, the course of MS was relatively mild, and like in three out of four other known cases, the symptoms of Wilson\u2019s disease were mostly restricted to hepatic dysfunction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The case presented in our report is similar to those reported before. The co-occurrence of the two diseases seems to be more a coincidence than a sharing of common factors in their pathogenesis; however, they are considered to influence one another. Regarding rare co-occurrences such as this one, every new case is of high importance, as it enables a better evaluation and understanding of the clinical presentations that are more characteristic of these cases, thus aiding the estimation of disease course as well as possible therapeutic choices.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-02691-5","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T06:02:44Z","timestamp":1652680964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Rare co-occurrence of multiple sclerosis and Wilson\u2019s disease \u2013 case report"],"prefix":"10.1186","volume":"22","author":[{"given":"Katalin","family":"Despotov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Kliv\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"P\u00e1lv\u00f6lgyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"V\u00e9csei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0252-4778","authenticated-orcid":false,"given":"Cec\u00edlia","family":"Rajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"issue":"3","key":"2691_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jhep.2011.11.007","volume":"56","author":"European Association for the Study of the Liver","year":"2012","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: Wilson\u2019s disease. J Hepatol. 2012;56(3):671\u201385.","journal-title":"J Hepatol"},{"key":"2691_CR2","doi-asserted-by":"crossref","unstructured":"Folhoffer A, Ferenci P, Cs\u00e1k T, Horv\u00e1th A, Heged\u00fbs D, Firneisz G, et al. Genetic and clinical characteristics of Wilson disease in patients from Hungary. Z Gastroenterol. 2008;46(5):A20.","DOI":"10.1055\/s-2008-1079624"},{"issue":"2","key":"2691_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373.","journal-title":"Lancet Neurol"},{"issue":"4","key":"2691_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/ana.21117","volume":"61","author":"A Ascherio","year":"2007","unstructured":"Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007;61(4):288\u201399.","journal-title":"Ann Neurol"},{"issue":"6","key":"2691_CR5","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/ana.21141","volume":"61","author":"A Ascherio","year":"2007","unstructured":"Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol. 2007;61(6):504\u201313.","journal-title":"Ann Neurol"},{"issue":"1\u20132","key":"2691_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jneuroim.2003.08.017","volume":"143","author":"C Rajda","year":"2003","unstructured":"Rajda C, Bencsik K, Seres E, Jonasdottir A, Foltynie T, Sawcer S, et al. A genome-wide screen for association in Hungarian multiple sclerosis. J Neuroimmunol. 2003;143(1\u20132):84\u20137.","journal-title":"J Neuroimmunol"},{"issue":"3","key":"2691_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.msard.2013.09.002","volume":"3","author":"K Dzie\u017cyc","year":"2014","unstructured":"Dzie\u017cyc K, Litwin T, Cz\u0142onkowska A. Multiple sclerosis in two patients with coexisting Wilson\u2019s disease. Mult Scler Relat Disord. 2014;3(3):387\u201390.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"2691_CR8","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00115-009-2876-0","volume":"81","author":"P G\u00fcnther","year":"2010","unstructured":"G\u00fcnther P, Baum P, Then BF. Morbus Wilson und multiple Sklerose. Nervenarzt. 2010;81(2):226\u20138.","journal-title":"Nervenarzt."},{"key":"2691_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2019.105507","volume":"186","author":"MF Yetkin","year":"2019","unstructured":"Yetkin MF, Mirza M, Gursoy S. Multiple sclerosis and Wilson disease: a rare coincidence. Clin Neurol Neurosurg. 2019;186:105507.","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"2691_CR10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292\u2013302.","journal-title":"Ann Neurol"},{"key":"2691_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clineuro.2015.07.013","volume":"138","author":"A Ranjan","year":"2015","unstructured":"Ranjan A, Kalita J, Kumar S, Bhoi SK, Misra UK. A study of MRI changes in Wilson disease and its correlation with clinical features and outcome. Clin Neurol Neurosurg. 2015;138:31\u20136.","journal-title":"Clin Neurol Neurosurg"},{"issue":"10","key":"2691_CR12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/jnnp.2009.204651","volume":"82","author":"JM Trocello","year":"2011","unstructured":"Trocello JM, Guichard JP, Leyendecker A, Pernon M, Chaine P, El Balkhi S, et al. Corpus callosum abnormalities in Wilson\u2019s disease. J Neurol Neurosurg Psychiatry. 2011;82(10):1119\u201321.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2691_CR13","doi-asserted-by":"crossref","unstructured":"Zhou ZH, Wu YF, Cao J, Hu JY, Han YZ, Hong MF, et al. Characteristics of neurological Wilson\u2019s disease with corpus callosum abnormalities. BMC Neurol. 2019;19(1):1\u20135.","DOI":"10.1186\/s12883-019-1313-7"},{"key":"2691_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jocn.2018.10.096","volume":"59","author":"W Zhong","year":"2019","unstructured":"Zhong W, Huang Z, Tang X. A study of brain MRI characteristics and clinical features in 76 cases of Wilson\u2019s disease. J Clin Neurosci. 2019;59:167\u201374.","journal-title":"J Clin Neurosci"},{"key":"2691_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/03014460.2015.1051492","volume":"43","author":"A Gomes","year":"2016","unstructured":"Gomes A, Dedoussis GV. Geographic distribution of ATP7B mutations in Wilson disease. Ann Hum Biol. 2016;43:1\u20138.","journal-title":"Ann Hum Biol"},{"issue":"2","key":"2691_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/mds.20671","volume":"21","author":"G Gromadzka","year":"2006","unstructured":"Gromadzka G, Schmidt HHJ, Genschel J, Bochow B, Rodo M, Tarnacka B, et al. p.H1069Q mutation in ATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson\u2019s disease. Mov Disord. 2006;21(2):245\u20138.","journal-title":"Mov Disord"},{"issue":"1","key":"2691_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.neurol.2015.10.006","volume":"172","author":"E Leray","year":"2016","unstructured":"Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol. 2016;172(1):3\u201313.","journal-title":"Rev Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02691-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02691-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02691-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T06:03:16Z","timestamp":1652680996000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02691-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2691"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02691-5","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"assertion":[{"value":"15 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for to participate was obtained from the patient. All investigations including human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Katalin Despotov has received support for congress participation from Teva. P\u00e9ter Kliv\u00e9nyi has not reported conflict of interest. Istv\u00e1n Nagy has not reported conflict of interest. Attila P\u00e1lv\u00f6lgyi has not reported conflict of interest. L\u00e1szl\u00f3 V\u00e9csei has served as advisory board member and has received support for congress participation or received speaker honoraria from Biogen, Merck, Novartis, Roche, Sanofi Genzyme, and Teva. Cecilia Rajda has received support for congress participation from Roche and Biogen, received honoraria for lecturing from Teva.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"178"}}